Cardiovascular toxicity of anti-angiogenic drugs

Targeted Oncology

Volumn 6, Issue 4, 2011, Pages 197-202

  Des Guetz, Gaetan ^a   Uzzan, Bernard ^a   Chouahnia, Kader ^a   Morère, Jean François ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

Adverse effects; Angiogenesis inhibitors; Blood pressure; Chemically induced; Myocardial ischemia; Vascular diseases

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; SORAFENIB; SUNITINIB; VANDETANIB;

ARTERY THROMBOSIS; BLEEDING; BLEEDING RISK; BLOOD PRESSURE MONITORING; BRADYCARDIA; BREAST CANCER; CARDIOTOXICITY; CARDIOVASCULAR RISK; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; DIASTOLIC BLOOD PRESSURE; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; GASTROINTESTINAL STROMAL TUMOR; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); NEUTROPENIA; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; QT PROLONGATION; REVIEW; RISK; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOLID TUMOR; STROKE; SYSTOLIC BLOOD PRESSURE; TAKOTSUBO CARDIOMYOPATHY; THROMBOEMBOLISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; TORSADE DES POINTES; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; HEART DISEASES; HUMANS;

EID: 84856027412     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-011-0204-7     Document Type: Review

References (36)

1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
2. des Guetz G, Uzzan B, Nicolas P et al (2006) Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 94:1823-1832 (Pubitemid 43882572)
3. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434 (Pubitemid 36910021)
4. Hurwitz H, Fehrenbacher L, Novotny Wet al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342 (Pubitemid 38702844)
5. Yeh ETH, Tong AT, Lenihan DJ, Yusuf SW et al (2004) Cardiovascular complications of cancer therapy. Diagnosis, pathogenesis, and management. Circulation 109:3122-3131
6. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65
7. An MM, Zou Z, Shen H, Ping L et al (2010) Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated analysis. Eur J Clin Pharmacol 66:813-821
8. Chu TF, Rupnick MA, Kerkela R et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011-2019 (Pubitemid 350236338)
9. Veronese ML, Mosenkis A, Flaherty KT et al (2006) Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24:1363-1369 (Pubitemid 46621999)
10. Wu S, Chen JJ, Kudelka A, Lu J et al (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9:117-123
11. Zhu X, Stergiopoulos K, Wu S (2009) Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 48:9-17
12. Nazer B, Humphreys BD, Moslehi J (2011) Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system. Focus on hypertension. Circulation 124:1687-1691
13. Mourad JJ, des Guetz G, Debbabi H, Levy BI (2008) Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 19:927-934 (Pubitemid 351627309)
14. Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49:186-193 (Pubitemid 46178407)
15. Eremina V, Quaggin SE (2010) Biology of anti-angiogenic therapy-induced thrombotic microangiopathy. Semin Nephrol 30:582-590
16. Eremina V, Jefferson JA, Kowalewska J, Hochster H et al (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358:1129-1136 (Pubitemid 351398487)
17. Scappaticci FA, Skillings JR, Holden SN et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232-1239 (Pubitemid 47299901)
18. Ranpura V, Hapani S, Chuang J, Wu S (2010) Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncol 49:287-297
19. Hurwitz HI, Saltz LB, van Cutsem E et al (2011) Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 29:1757-1754
20. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:2277-2285
21. Hapani S, Sher A, Chu D, Wu S (2010) Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 79:27-38
22. Hang XF, Xu WS, Wang JX, Xin H et al (2011) Risk of highgrade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 67:613-623
23. Franco TH, Khan A, Joshi V, Thomas B (2008) Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag 4:1367-1370
24. Choueiri TK, Mayer EL, Je Y, Rosenberg JE et al (2011) Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 29:632-638
25. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124 (Pubitemid 46089672)
26. Motzer RJ, Rini BI, Bukowski RM, Curti BD et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524 (Pubitemid 43854967)
27. Escudier B, Eisen T, Stadler WM, Szczylik C et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134 (Pubitemid 46089673)
28. Schmidinger M, Zielinski CC, Vogl UM, Bojic A et al (2008) Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204-5212
29. Popat S, Smith IE (2008) Therapy insight: anthracyclines and trastuzumab-the optimal management of cardiotoxic side effects. Nature Clin Pract 5:324-335 (Pubitemid 351780949)
30. Suter TM, Cook-Bruns N, Barton C (2004) Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. The Breast 13:173-183 (Pubitemid 38937119)
31. Kiura K, Nakagawa K, Shinkai T et al (2008) A randomized, double-blind, phase IIa dose-finding study of vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 3:386-393 (Pubitemid 351489479)
32. Maitland ML, Bakris GL, Black HR et al (2010) Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors. JNCI 102:596-604
33. Galfrascoli E, Piva S, Cinquini M et al (2011) Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis 43:286-294
34. Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients. A meta-analysis. JAMA 305:487-494
35. Boehm S, Rothermundt C, Hess D, Joerger M (2010) Antiangiogenic drugs in oncology: A focus on drug safety and the elderly-A mini-review. Gerontology 56:303-309
36. Ederhy S, Izzedine H, Massard C, Dufaitre G, Spano JP, et al (2011) Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol 2011 Feb 15 [Epub ahead of print]